share_log

中國中藥：截至二零二四年一月三十一日止月份之股份發行人的證券變動月報表

TRAD CHI MED: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024

香港交易所 ·  Feb 1 03:46
Summary by Moomoo AI
中國中藥控股有限公司（股份代號：00570）於2024年1月31日提交了新的證券變動月報表。該報表由聯席公司秘書趙東吉於2024年2月1日向香港交易及結算所有限公司呈交。報表中確認，該公司在1月份沒有發行新的股份或預託證券，並且所有已發行的股份在各方面均屬相同，包括面值、股款、股息/利息計算及派發、以及附帶的權益。此外，報表中提到，所有必要的法律文件已經存檔，並且所有相關的交易條件已經履行，包括收取全部款項、履行上市先決條件、完成物業購買交易及繳付代價等。報表中未提及有關股份期權、權證、可換股票據或其他協議的變動。
中國中藥控股有限公司（股份代號：00570）於2024年1月31日提交了新的證券變動月報表。該報表由聯席公司秘書趙東吉於2024年2月1日向香港交易及結算所有限公司呈交。報表中確認，該公司在1月份沒有發行新的股份或預託證券，並且所有已發行的股份在各方面均屬相同，包括面值、股款、股息/利息計算及派發、以及附帶的權益。此外，報表中提到，所有必要的法律文件已經存檔，並且所有相關的交易條件已經履行，包括收取全部款項、履行上市先決條件、完成物業購買交易及繳付代價等。報表中未提及有關股份期權、權證、可換股票據或其他協議的變動。
CHINA PHARMACEUTICAL HOLDINGS LIMITED (STOCK CODE: 00570) FILED A NEW MONTHLY STATEMENT OF CHANGES IN SECURITIES ON 31 JANUARY 2024. The report was submitted to Hong Kong Trading and Settlement Limited on 1 February 2024 by the Joint Secretary of the Joint Company, Zhao Tongji. The report confirms that the Company did not issue any new shares or pre-trust securities in January and that all issued shares are identical in all respects, including face value, shares, dividend/interest calculation and distribution, and attached interests. In addition, it is mentioned in the report that all necessary legal documents have been archived and all relevant transaction conditions have been met, including collection of all payments, fulfillment of listing prerequisites, completion of property purchase transactions and payment of fees, etc. Changes in stock options, warrants, convertible notes, or other agreements are not mentioned in the report.
CHINA PHARMACEUTICAL HOLDINGS LIMITED (STOCK CODE: 00570) FILED A NEW MONTHLY STATEMENT OF CHANGES IN SECURITIES ON 31 JANUARY 2024. The report was submitted to Hong Kong Trading and Settlement Limited on 1 February 2024 by the Joint Secretary of the Joint Company, Zhao Tongji. The report confirms that the Company did not issue any new shares or pre-trust securities in January and that all issued shares are identical in all respects, including face value, shares, dividend/interest calculation and distribution, and attached interests. In addition, it is mentioned in the report that all necessary legal documents have been archived and all relevant transaction conditions have been met, including collection of all payments, fulfillment of listing prerequisites, completion of property purchase transactions and payment of fees, etc. Changes in stock options, warrants, convertible notes, or other agreements are not mentioned in the report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more